Talk Bio

A federal judge in New Jersey ruled on October 26 that Eli Lilly can keep running ads comparing its obesity drugs with Novo Nordisk’s while Novo’s lawsuit proceeds. Judge Zahid Quraishi denied Novo’s request for a preliminary injunction, finding it had not shown the ads caused irreparable damage to sales, goodwill, or clinical reputation. Novo prescriptions remained stable during the period examined. The ruling does not decide whether Lilly’s advertising is false or misleading. The underlying lawsuit, filed by Novo in July, is ongoing. The judge described Novo’s case as “less than persuasive” on the preliminary record. He also noted concerns about Novo’s own comparative advertising, but that did not resolve the merits of the dispute. Sources: US judge refuses to block Eli Lilly weight-loss drug ads, ... Novo Nordisk Loses US Ruling Over Eli Lilly Obesity Drug Ads (2) Eli Lilly fends off Novo's legal bid to block GLP-1 marketing claims Novo Nordisk Loses Court Ruling...